Introduction
The cited FDA labels describe tirzepatide as an injection. Zepbound and Mounjaro have evidence for approved injectable tirzepatide; an oral tirzepatide offer needs independent verification of its formulation and FDA status.
Injection trial results do not establish that an oral product has the same absorption, quality, or clinical effect.
What is currently supported by the cited labels
Zepbound and Mounjaro prescribing information describe tirzepatide injection. Zepbound is labeled for chronic weight management and Mounjaro for type 2 diabetes. The first task with an oral offer is to confirm exactly what it is, rather than assuming it matches the approved injection.
We may earn a commission if you start a program through links on this page. It doesn't change prices or how we sort them. Disclosure
LIVE CATALOGCurrent telehealth prices and providers
Some provider links below are affiliate links. If you start a program through one, Telehealth Ledger may earn a commission at no extra cost to you. Commissions do not change this order.
These rows come from Telehealth Ledger's canonical catalog. A low headline price only ranks when medication is included and the continuing or prepaid basis is comparable.
| Provider | Published price | What is included |
|---|---|---|
| #1 PlexusDx | $189compounded (not FDA-approved), checked 22 October 2026 a month, continuing Visit provider Affiliate link · we may earn a commission | Tirzepatide Oral · Daily oral tablets, provider-titrated; one price at every dose · medication included Month-to-month is $189, billed monthly. A 3-month plan is $169/mo ($507 up front), a 6-month plan is $149/mo ($894 up front), and a 12-month plan is $129/mo ($1,548 up front). The page calls $129 the starting price. Same price at every dose. Provider visit, medication, and shipping are included. No membership fee. Price source · checked 22 October 2026 |
| #2 Strut Health | $199compounded (not FDA-approved), checked 20 October 2026 a month, continuing Visit provider Affiliate link · we may earn a commission | Oral tirzepatide · 30-day sublingual lozenge supply · medication includedPrice source · checked 20 October 2026 |
| #3 RxSpan MD | $349compounded (not FDA-approved), checked 22 October 2026 a month, continuing Visit provider Affiliate link · we may earn a commission | Tirzepatide Oral Capsules · Oral capsules · medication included The weight-loss category calls $349 the Regular Monthly Price for Tirzepatide Capsules. A separate line says as low as $243/mo on a 12-month plan billed as $2,905 upfront. That promo rate is not the regular monthly price. Price source · checked 22 October 2026 |
| #4 Willow | $399compounded (not FDA-approved), checked 20 October 2026 a month, continuing Visit provider Affiliate link · we may earn a commission | Compounded Tirzepatide Tablets · Daily oral dissolving tablet, monthly auto-renewing subscription · medication includedPrice source · checked 20 October 2026 |
- Curex: $149 first month starting price; exact renewal quote after intakecompounded (not FDA-approved)Last checked 7 Oct 2026Medication included as published
- HumeCare+: Introductory offer from $199/mo • automatic refills, cancel anytimecompounded (not FDA-approved)Last checked 14 Sept 2026Medication included as published
- RxSpan MD: $897 prepaid / 3 months ($299/mo effective)compounded (not FDA-approved)Last checked 14 Sept 2026Medication included as published
| Provider | Published price | What is included |
|---|---|---|
| #1 Sesame Care | $299, checked 20 October 2026 a month, continuing; plus $99/month care Visit provider Affiliate link · we may earn a commission | Zepbound® KwikPen · Weekly injection · medication included Medication dose prices: $299/month at 2.5 mg; $398 at 5 mg; $499 at 7.5 mg; $698 at 10, 12.5 or 15 mg. The calculation uses the 2.5 mg price; a dose change changes the total. Care is $99/month separately; $59/month requires an annual care commitment. Price source · checked 20 October 2026 |
| #2 RxSpan MD | $1,069, checked 22 October 2026 a month, continuing Visit provider Affiliate link · we may earn a commission | Zepbound® · Weekly branded injection · medication included The weight-loss category card prints $1,069 (For the first month). It does not print a separate later monthly price. Price source · checked 22 October 2026 |
| #3 GobyMeds | $1,399, checked 22 October 2026 a month, continuing Visit provider | Zepbound® · Weekly injection · medication includedPrice source · checked 22 October 2026 |
- DrHouse: $129 self-pay visit or insurance copayMedication or membership billed separately
- Hone Health: Estimated from $349/mo plus membershipMedication or membership billed separately
- Measured: Product page $99/mo membership; homepage from $49; medication separate ($299–$449/mo cash range)Last checked 7 Oct 2026Medication or membership billed separately
- DrHouse: $129 self-pay visit or insurance copayMedication or membership billed separately
- RxSpan MD: $1,069 / month; org catalog also marks this SKU sold outLast checked 14 Sept 2026Medication included as published
| Provider | Published price | What is included |
|---|---|---|
| #1 CoreAge Rx | $129compounded (not FDA-approved), checked 22 October 2026 a month, paying $1,548 for 12 months up front Visit provider Affiliate link · we may earn a commission | Compounded tirzepatide injection · Injection · medication includedPrice source · checked 22 October 2026 |
| #2 yourEra | $129compounded (not FDA-approved), checked 22 October 2026 a month, continuing Visit provider Affiliate link · we may earn a commission | Compounded Tirzepatide month-to-month · Weekly subcutaneous injection; month-to-month · medication included Checked 22 October 2026. Month-to-month tirzepatide is $129/mo after a 20% discount the page says is auto-applied. The pre-discount figure on the page is $161.25. The page does not show the old $99 12-month plan. Price source · checked 22 October 2026 |
| #3 GobyMeds | $133compounded (not FDA-approved), checked 22 October 2026 a month, paying $399 for 3 months up front Visit provider | Compounded Tirzepatide Starter Plan · Weekly injection · medication includedPrice source · checked 22 October 2026 |
| #4 SnagRX | $149compounded (not FDA-approved), checked 22 October 2026 a month, continuing Visit provider Affiliate link · we may earn a commission | Compounded tirzepatide injection · Weekly subcutaneous injection · medication includedPrice source · checked 22 October 2026 |
| #5 Strut Health | $149compounded (not FDA-approved), checked 22 October 2026 a month, continuing Visit provider Affiliate link · we may earn a commission | Tirzepatide injection · Once-weekly subcutaneous injection · medication includedPrice source · checked 22 October 2026 |
Showing the 5 lowest comparable published prices from 18 eligible providers. The complete comparison includes every current catalog row.
- bmiMD: $229/mo effective • $687 prepaid every 3 monthscompounded (not FDA-approved)Last checked 14 Sept 2026Medication included as published
- bmiMD: $189/mo effective • $1,134 prepaid every 6 monthscompounded (not FDA-approved)Last checked 14 Sept 2026Medication included as published
- Curex: $149 first month starting price; exact renewal quote after intakecompounded (not FDA-approved)Last checked 7 Oct 2026Medication included as published
Eligibility, prescribed quantity, state availability, pharmacy fulfillment, shipping, supplies, and follow-up can change the final cost. Unknown fields remain unknown.
What injection trials can show
SURMOUNT-1 studied once-weekly injectable tirzepatide in adults with obesity or overweight plus a weight-related condition, without diabetes. At 72 weeks, mean change ranged from -15.0% to -20.9% across tirzepatide groups. The trial does not establish an oral counterpart or a route conversion.
| Decision point | What the cited evidence can answer |
|---|---|
| Exact product | Confirm the approved indication, route, and formulation |
| Outcome evidence | Keep direct trials separate from indirect study comparisons |
| Practical fit | Review safety history, other medicines, follow-up, and access |
What to verify before comparing an oral offer
Ask for the active ingredient, dosage form, FDA status, prescriber, dispensing pharmacy, formulation, and written instructions. If the product is compounded or otherwise non-approved, FDA's compounded-drug concerns apply and an approved injection label should not be used as a substitute for product-specific information.
Why conversion claims fail
Route, formulation, absorption, and product instructions can differ. Do not use an editorial page to convert milligrams or advise switching.
| Question | Evidence-based check |
|---|---|
| Exact product | Confirm the approved product, formulation, and labeled indication |
| Evidence | Keep direct trials separate from indirect comparisons |
| Access | Verify provider terms and price basis independently |
Compounding is a separate safety layer
FDA says compounded GLP-1 products are not FDA-approved and has described formulation and dosing concerns.
Verify before comparing price
A price card should state exact form and product status. Hide entries lacking current source evidence.
What the cited sources establish
The cited current Zepbound and Mounjaro labels describe injectable tirzepatide. SURMOUNT-1 supports an approved injectable trial regimen in its enrolled population, not an oral offer. Any future oral tirzepatide claim needs current, product-specific FDA status and evidence rather than an inference from injection studies.
An oral offer needs a different evidence trail from an approved injection. The key record is the current product label or regulatory source for that exact oral formulation, plus clear pharmacy documentation if it is compounded. Until that record exists, SURMOUNT-1 can describe injectable tirzepatide outcomes but cannot answer an oral product's absorption, handling, quality, or clinical-effect question.
The route question has two separate parts: what is currently verified, and what would make the route workable in a person's care plan. Current cited FDA labels establish the approved injections. An oral product would need its own reliable identity, status, instructions, and evidence before the practical issues of routine, tolerance, other medicines, and access can be compared fairly. Skipping the verification step leaves the central product question unanswered.
Questions that change the next review
Before comparing route or price, identify the offered product in writing: active ingredient, dosage form, FDA status, prescriber, dispensing pharmacy, and instructions. If an oral offer is compounded or otherwise non-approved, the clinician and pharmacy need to evaluate that exact preparation rather than borrowing the injection label.
Route selection starts only after the product can be identified. Once an oral offer has current status and formulation records, the care team can compare practicality and safety with the approved injections.
Product details that still need verification
No oral-to-injectable milligram conversion is supported here. Injection efficacy data do not prove oral absorption, stability, quality, or clinical equivalence. The article also cannot confirm a changing market claim without current FDA material and a verified product record.
Publication-day status verification is required. Do not compare oral and injectable milligrams. Approved injection trials do not validate oral offers. Unclear labeling is a reason to pause and verify. The FDA labels cited here describe tirzepatide as an injection. Any oral tirzepatide offer needs a current verification of formulation and FDA status; do not imply that an oral compounded product has the same evidence, quality review, or dose equivalence as an approved injection. The next step is a clinician-led review of the exact product and your situation.
Use the current product label and prompt clinical care for urgent symptoms or medication changes.
Common questions
- What does the evidence show about Oral vs Injectable Tirzepatide: FDA Status, Formulation Questions, and What to Verify?
- The FDA labels cited here describe tirzepatide as an injection. Any oral tirzepatide offer needs a current verification of formulation and FDA status; do not imply that an oral compounded product has the same evidence, quality review, or dose equivalence as an approved injection.
- Can I use this as dosing or switching advice?
- No. This page excludes personalized dosing, conversions, and self-directed treatment changes.
- What should I check before acting?
- Check the current product label, the exact formulation, and the plan with the prescribing clinician.
- Why are labels named so often?
- Products can share an ingredient while having different approved uses, formulations, warnings, and evidence.
Use evidence to improve the next clinical conversation
The FDA labels cited here describe tirzepatide as an injection. Any oral tirzepatide offer needs a current verification of formulation and FDA status; do not imply that an oral compounded product has the same evidence, quality review, or dose equivalence as an approved injection. The next step is a clinician-led review of the exact product and your situation.
Already on a oral tirzepatide plan? See which of 4 providers charge less than yours
Starting from scratch? How to get compounded oral tirzepatide online
Sources
- FDA primary materialFDA · Accessed 28 August 2026
Primary evidence supporting oral vs injectable tirzepatide.
- FDA primary materialFDA · Accessed 28 August 2026
Primary evidence supporting oral vs injectable tirzepatide.
- Clinical study recordPubMed · Accessed 28 August 2026
Primary evidence supporting oral vs injectable tirzepatide.
- FDA primary materialFDA · Accessed 28 August 2026
Primary evidence supporting oral vs injectable tirzepatide.
- FDA primary materialFDA · Accessed 28 August 2026
Primary evidence supporting oral vs injectable tirzepatide.
Refresh triggers
- A new FDA label or Medication Guide
- A new major clinical-trial publication
- An ADA or AGA guideline update
- A material change to the verified provider registry